The aim of this platform is to offer all patients in the former Lower Normandy region, regardless of the facility where they are treated, equal access to molecular tests for cancer, enabling them to initiate the most appropriate targeted therapy.
For the pathologies in question, the aim is to analyze certain biomarkers whose mutational status within the tumor is crucial for accessing new therapies. These targeted therapies thus constitute "tailor-made" treatments adapted to the molecular characteristics of the patient's tumor.
